GlaxoSmithKline Plans Vaccine Plant in Singapore

June 16, 2006
Patricia Van Arnum

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

ePT--the Electronic Newsletter of Pharmaceutical Technology

GlaxoSmithKline PLC (GSK, London, UK) will invest more than GBP102 million ($188 million) over the next four years in a vaccine manufacturing plant in Singapore.

GlaxoSmithKline PLC (GSK, London, UK, www.gsk.com) will invest more than GBP102 million($188 million) over the next four years in a vaccine manufacturingplant in Singapore.

The facility will be dedicated to the primary production of pediatricvaccines. Once operational, the facility will manufacture GSK'sconjugate vaccine, which provides protection against Streptococcus pneumoniae andnontypeable Haemophilus influenzae.

In 2005, GSK opened its Center for Research in Cognitive andNeurodegenerative Disorders in Singapore's Biopolis and also announcedplans to build a research and development pilot plant at its globalmanufacturing supply site in Jurong.